Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin Lymphoma Pipeline Drugs Market Report Overview
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery, radiation therapy, and chemotherapy.
The NHL pipeline drugs market research report provides comprehensive information on the therapeutics under development for NHL, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for the NHL and features dormant and discontinued projects.
NHL Pipeline Drugs Market Segmentation by Targets
Some of the targets of the NHL pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, Cells Expressing B Cell Receptor CD22, CD3, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Programmed Cell Death Protein 1, Leukocyte Surface Antigen CD47, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, and others.
NHL Pipeline Drugs Market Analysis, by Targets
For more NHL pipeline drugs market target insights, download a free report sample
NHL Pipeline Drugs Market Segmentation by Mechanisms of Action
Some of the key mechanisms of action of the NHL pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, CD3 Agonist, Programmed Cell Death Protein 1 Antagonist, Leukocyte Surface Antigen CD47 Inhibitor, and others.
NHL Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the NHL pipeline drugs market, download a free report sample
NHL Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the NHL pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, topical, intramuscular, and others.
NHL Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the NHL pipeline drugs market, download a free report sample
NHL Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the NHL pipeline drugs market are Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Synthetic Peptide, Recombinant Protein, and others.
NHL Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the NHL pipeline drugs market, download a free report sample
NHL Pipeline Drugs Market - Competitive Landscape
Some of the key companies in the NHL pipeline drugs market are Bristol-Myers Squibb Co, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Gracell Biotechnologies Inc, Merck & Co Inc, AbbVie Inc, BeiGene Ltd, and others.
NHL Pipeline Drugs Market Analysis, by Companies
To know more about the NHL pipeline drugs market companies, download a free report sample
NHL Pipeline Drugs Market Report Overview
| Key Targets | Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, Cells Expressing B Cell Receptor CD22, CD3, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Programmed Cell Death Protein 1, Leukocyte Surface Antigen CD47, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, and Others |
| Key Mechanisms of Action | Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, CD3 Agonist, Programmed Cell Death Protein 1 Antagonist, Leukocyte Surface Antigen CD47 Inhibitor, and Others |
| Key Routes of Administration | Intravenous, Oral, Parenteral, Subcutaneous, Intratumor, Intravenous Drip, Topical, Intramuscular, and Others |
| Key Molecule Types | Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Synthetic Peptide, Recombinant Protein, and Others |
| Key Companies | Bristol-Myers Squibb Co, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Gracell Biotechnologies Inc, Merck & Co Inc, AbbVie Inc, BeiGene Ltd, and Others |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of NHL.
- The pipeline guide reviews pipeline therapeutics for NHL by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in NHL therapeutics and enlists NHL in their major and minor projects.
- The pipeline guide evaluates NHL therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates NHL in the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for NHL
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for NHL.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the NHL pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Some of the targets of the NHL pipeline drugs market are Cells Expressing B Lymphocyte Antigen CD19, Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK, Cells Expressing B Cell Receptor CD22, CD3, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform, Programmed Cell Death Protein 1, Leukocyte Surface Antigen CD47, Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 8, and others.
Some of the mechanisms of action of the NHL pipeline drugs market are Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Tyrosine Protein Kinase BTK Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Delta Isoform Inhibitor, CD3 Agonist, Programmed Cell Death Protein 1 Antagonist, Leukocyte Surface Antigen CD47 Inhibitor, and others.
The key routes of administration in the NHL pipeline drugs market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, topical, intramuscular, and others.
The molecule types in the NHL pipeline drugs market are Small Molecule, Gene-Modified Cell Therapy, Monoclonal Antibody, Monoclonal Antibody Conjugated, Cell Therapy, Fusion Protein, Synthetic Peptide, Recombinant Protein, and others.
Some of the key companies in the NHL pipeline drugs market are Bristol-Myers Squibb Co, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc, Gracell Biotechnologies Inc, Merck & Co Inc, AbbVie Inc, BeiGene Ltd, and others.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Related reports
View more Oncology reports